Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/307% above fair value
$951.19−8.22 (-0.86%)
Close on Nov 12, 2026Market cap $98.40BP/E 21.0Yield –
Regeneron Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Regeneron Pharmaceuticals's total assets was $44.41B at Sep 30, 2026. For fiscal 2025 it was $40.56B, up 7.4% from the year before. Over ten years it grew 21.9% a year on average. The highest annual figure on record is $40.56B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.56B | +7.4% |
| FY2024 | Dec 31, 2024 | $37.76B | +14.1% |
| FY2023 | Dec 31, 2023 | $33.08B | +13.2% |
| FY2022 | Dec 31, 2022 | $29.21B | +14.9% |
| FY2021 | Dec 31, 2021 | $25.43B | +48.2% |
| FY2020 | Dec 31, 2020 | $17.16B | +15.9% |
| FY2019 | Dec 31, 2019 | $14.81B | +26.2% |
| FY2018 | Dec 31, 2018 | $11.73B | +33.9% |
| FY2017 | Dec 31, 2017 | $8.76B | +25.7% |
| FY2016 | Dec 31, 2016 | $6.97B | +24.3% |
| FY2015 | Dec 31, 2015 | $5.61B | +46.2% |
| FY2014 | Dec 31, 2014 | $3.84B | +30.0% |
| FY2013 | Dec 31, 2013 | $2.95B | +41.8% |
| FY2012 | Dec 31, 2012 | $2.08B | +57.2% |
| FY2011 | Dec 31, 2011 | $1.32B | +21.5% |
| FY2010 | Dec 31, 2010 | $1.09B | +47.0% |
| FY2009 | Dec 31, 2009 | $741.20M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $44.41B | +10.5% |
| Q2 FY2026 | Jun 30, 2026 | $41.73B | +9.2% |
| Q1 FY2026 | Mar 31, 2026 | $40.87B | +8.9% |
| Q4 FY2025 | Dec 31, 2025 | $40.56B | +7.4% |
| Q3 FY2025 | Sep 30, 2025 | $40.17B | +7.3% |
| Q2 FY2025 | Jun 30, 2025 | $38.22B | +5.9% |
| Q1 FY2025 | Mar 31, 2025 | $37.55B | +9.2% |
| Q4 FY2024 | Dec 31, 2024 | $37.76B | +14.1% |
| Q3 FY2024 | Sep 30, 2024 | $37.44B | +16.4% |
| Q2 FY2024 | Jun 30, 2024 | $36.09B | +17.7% |
| Q1 FY2024 | Mar 31, 2024 | $34.37B | +14.3% |
| Q4 FY2023 | Dec 31, 2023 | $33.08B | +13.2% |
| Q3 FY2023 | Sep 30, 2023 | $32.16B | +16.2% |
| Q2 FY2023 | Jun 30, 2023 | $30.66B | +12.7% |
| Q1 FY2023 | Mar 31, 2023 | $30.06B | +14.1% |
| Q4 FY2022 | Dec 31, 2022 | $29.21B | +14.9% |
| Q3 FY2022 | Sep 30, 2022 | $27.68B | +16.9% |
| Q2 FY2022 | Jun 30, 2022 | $27.21B | +26.6% |
| Q1 FY2022 | Mar 31, 2022 | $26.35B | +48.3% |
| Q4 FY2021 | Dec 31, 2021 | $25.43B | +48.2% |
| Q3 FY2021 | Sep 30, 2021 | $23.67B | +47.2% |
| Q2 FY2021 | Jun 30, 2021 | $21.49B | +48.9% |
| Q1 FY2021 | Mar 31, 2021 | $17.77B | +12.8% |
| Q4 FY2020 | Dec 31, 2020 | $17.16B | +15.9% |
| Q3 FY2020 | Sep 30, 2020 | $16.08B | +15.4% |
| Q2 FY2020 | Jun 30, 2020 | $14.43B | +9.5% |
| Q1 FY2020 | Mar 31, 2020 | $15.76B | +22.6% |
| Q4 FY2019 | Dec 31, 2019 | $14.81B | +26.2% |
| Q3 FY2019 | Sep 30, 2019 | $13.94B | +29.0% |
| Q2 FY2019 | Jun 30, 2019 | $13.17B | +32.4% |
| Q1 FY2019 | Mar 31, 2019 | $12.85B | +37.2% |
| Q4 FY2018 | Dec 31, 2018 | $11.73B | +33.9% |
| Q3 FY2018 | Sep 30, 2018 | $10.81B | +24.2% |
| Q2 FY2018 | Jun 30, 2018 | $9.95B | +22.8% |
| Q1 FY2018 | Mar 31, 2018 | $9.37B | +19.9% |
| Q4 FY2017 | Dec 31, 2017 | $8.76B | +25.7% |
| Q3 FY2017 | Sep 30, 2017 | $8.70B | – |
| Q2 FY2017 | Jun 30, 2017 | $8.11B | – |
| Q1 FY2017 | Mar 31, 2017 | $7.82B | – |
| Q4 FY2016 | Dec 31, 2016 | $6.97B | – |
See a number that looks wrong?